Doxifluridine: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Doxifluridine''' is an | {{Short description|Overview of the chemotherapeutic agent Doxifluridine}} | ||
{{Drugbox | |||
| image = Doxifluridine.svg | |||
| image_size = 250px | |||
| image_alt = Structural formula of Doxifluridine | |||
}} | |||
'''Doxifluridine''' is an oral prodrug of the chemotherapeutic agent [[5-fluorouracil]] (5-FU), used in the treatment of various [[cancer|cancers]]. It is designed to enhance the delivery and efficacy of 5-FU by being converted into the active drug within the body. | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
Doxifluridine is metabolized | Doxifluridine is metabolized into 5-fluorouracil by the enzyme [[thymidine phosphorylase]], which is often found in higher concentrations in tumor tissues compared to normal tissues. This selective activation allows for higher concentrations of the active drug in cancerous tissues, potentially reducing systemic toxicity. | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
Doxifluridine is administered orally and is absorbed through the gastrointestinal tract. Once absorbed, it is converted into 5-fluorouracil in the liver and tumor tissues. The conversion process is facilitated by the presence of thymidine phosphorylase, which is more abundant in tumor cells, thus providing a targeted approach to chemotherapy. | |||
== | ==Clinical Use== | ||
Doxifluridine is | Doxifluridine is primarily used in the treatment of [[colorectal cancer]], [[breast cancer]], and [[gastric cancer]]. It is often used in combination with other chemotherapeutic agents to enhance its efficacy. The drug's ability to be selectively activated in tumor tissues makes it a valuable option in cancer therapy. | ||
== | ==Side Effects== | ||
As with many chemotherapeutic agents, doxifluridine can cause a range of side effects. Common side effects include [[nausea]], [[vomiting]], [[diarrhea]], and [[myelosuppression]]. Due to its selective activation, it may have a more favorable side effect profile compared to direct administration of 5-fluorouracil. | |||
== | ==Related pages== | ||
* [[5-fluorouracil]] | |||
* [[Chemotherapy]] | |||
* [[Cancer treatment]] | |||
[[Category: | [[Category:Chemotherapeutic agents]] | ||
[[Category:Prodrugs]] | [[Category:Prodrugs]] | ||
<gallery> | |||
File:Doxifluridine.svg|Doxifluridine | |||
</gallery> | |||
Latest revision as of 01:00, 20 February 2025
Overview of the chemotherapeutic agent Doxifluridine
| Doxifluridine | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Doxifluridine is an oral prodrug of the chemotherapeutic agent 5-fluorouracil (5-FU), used in the treatment of various cancers. It is designed to enhance the delivery and efficacy of 5-FU by being converted into the active drug within the body.
Mechanism of Action[edit]
Doxifluridine is metabolized into 5-fluorouracil by the enzyme thymidine phosphorylase, which is often found in higher concentrations in tumor tissues compared to normal tissues. This selective activation allows for higher concentrations of the active drug in cancerous tissues, potentially reducing systemic toxicity.
Pharmacokinetics[edit]
Doxifluridine is administered orally and is absorbed through the gastrointestinal tract. Once absorbed, it is converted into 5-fluorouracil in the liver and tumor tissues. The conversion process is facilitated by the presence of thymidine phosphorylase, which is more abundant in tumor cells, thus providing a targeted approach to chemotherapy.
Clinical Use[edit]
Doxifluridine is primarily used in the treatment of colorectal cancer, breast cancer, and gastric cancer. It is often used in combination with other chemotherapeutic agents to enhance its efficacy. The drug's ability to be selectively activated in tumor tissues makes it a valuable option in cancer therapy.
Side Effects[edit]
As with many chemotherapeutic agents, doxifluridine can cause a range of side effects. Common side effects include nausea, vomiting, diarrhea, and myelosuppression. Due to its selective activation, it may have a more favorable side effect profile compared to direct administration of 5-fluorouracil.
Related pages[edit]
-
Doxifluridine